|
Malignant Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
In the inverse setting; a second contradiction, high MAD2 expression in cancer patients generally correlates with abnormal chromosome number.
|
31593803 |
2020 |
|
Malignant Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
CMLD-2 treatment induced a strong MAD2 downregulation and rescue experiments depicted it as a key effector in HuR-mediated in cancer.
|
31089242 |
2019 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Our results showed that disruption of MAD2-p31<sup>comet</sup> axis by MAD2 knockdown or p31<sup>comet</sup> overexpression suppressed cell proliferation, survival and migration of glioma, indicating that MAD2-p31<sup>comet</sup> axis is required for maintaining glioma cells malignancy.
|
29408509 |
2018 |
|
Malignant Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
In conclusion, with the exception of ovarian cancer, increased MAD2 expression is associated with increased risk of all-cause mortality and recurrence in cancer.
|
29254238 |
2017 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Endogenous expression of MAD2γ and full-length MAD2 (MAD2α) was measured using RT-PCR in cancer cell lines, normal foreskin fibroblasts, and tumor samples collected from patients with testicular germ cell tumors (TGCTs).
|
27315568 |
2016 |
|
Malignant Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Thus, we hypothesized that Mad2 overexpression could specifically make cancer cells susceptible to death by inducing a synthetic dosage lethality defect.
|
24425774 |
2014 |
|
Malignant Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
We demonstrated that with the progression of CC, the expression of Bub1 and Mad2 was gradually reduced under the influence of HPVE5.
|
23128250 |
2013 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The Mad1-Mad2 balancing act--a damaged spindle checkpoint in chromosome instability and cancer.
|
23093575 |
2012 |
|
Malignant Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Our data validate the correlation between upregulation of Mad2 and osteosarcoma advancement, and that the underlying mechanisms involve the increase of invasiveness and cancer stem cell properties.
|
22992948 |
2012 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
This study suggested that Mad2 has potential to be a novel target for cancer therapy.
|
21901524 |
2011 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
High-level expression of mitotic arrest defective protein 2 (MAD2), a central component of the spindle assembly checkpoint, has been observed in a variety of human malignancies.
|
21376419 |
2011 |
|
Malignant Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
The Mad2 gene is very rarely mutated in many kinds of human cancer, but aberrantly reduced expression of MAD2 has been correlated with defective mitotic checkpoints in several human cancers.
|
20440596 |
2010 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Nek2 targets the mitotic checkpoint proteins Mad2 and Cdc20: a mechanism for aneuploidy in cancer.
|
20034488 |
2010 |
|
Malignant Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
We show that MAD2 down-regulation induces premature senescence in the MCF7 breast epithelial cancer cell line.
|
19935801 |
2009 |
|
Malignant Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Elevated MAD2 expression was observed in a number of human malignancies; its role in the development of hepatocellular carcinoma is still not understood and is controversial.
|
18715617 |
2008 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
In this issue of Cancer Cell, Sotillo and coworkers report that Mad2 overexpression leads to chromosomal instability and tumorigenesis, indicating that Mad2 contributes to cancer development after Rb mutation.In a second paper, Weaver et al. report that aneuploidy has both tumor-promoting and -suppressing properties.
|
17222786 |
2007 |
|
Malignant Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
So far, MAD2L2 has not been reported to play a major role in human cancer in contrast to its homologue MAD2.
|
17044027 |
2007 |
|
Malignant Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
This is the first report to show that Mad1, Mxi1 and Rox genes were expressed and displayed mutations in haematological malignancies.
|
17577784 |
2007 |
|
Malignant Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
This analysis predicts that cancer cells manifesting a stem cell-like expression profile of a death-from-cancer signature would exhibit the following features: a concomitantly increased expression of certain members of inhibitor of apoptosis protein (IAP) family (Survivin and XIAP); activation of mitotic spindle check point proteins (BUB1, BUB3, KNTC2, Mad2, PLK1, PLK4, STK6/Aurora A); and elevated levels of certain cell cycle control/marker proteins (CCNB1, CCNB2, CCND1, CCNA2, CDC2, CDC25, Ki67, USP22).
|
16760651 |
2006 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
No germline mutations in the dimerization domain of MXI1 in prostate cancer clusters. The CRC/BPG UK Familial Prostate Cancer Study Collaborators. Cancer Research Campaign/British Prostate Group.
|
9376279 |
1997 |
|
Malignant Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
MXI1 thus displays allelic loss and mutation in some cases of prostate cancer that may contribute to the pathogenesis or neoplastic evolution of this common malignancy.
|
7773287 |
1995 |